1.

EGFR突变与NSCLC放疗疗效的回顾性临床研究结果

Retrospective analysis on EGFR mutation and radiation treatment outcome for NSCLCs

Reference	Study type	Patients	RT schedule	Systemic therapy	Result			Md OS (month)
					WT	Mutated		WT	Mutated
EGFR: epidermal growth factor receptor; NSCLC: non-small cell lung cancer; TKI: tyrosine kinase inhibitor; RT: radiation therapy; WBRT: whole brain radiation therapy; RR: response rate; LRR: locoregional recurrence rate; RFS: relapse-free survival; WT: EGFR wild type; Mutated: EGFR mutated type; Md OS: median overall survival.
Gow CH. et al [19]	PhaseⅡ single institution (n=63)	Lung adenocarcinoma with brain metastases	WBRT 30 Gy-35 Gy/ 15 f-18 f	With or without TKI	RR (%): 24 (4/17)  54 (25/46) P=0.045			6.6  17.3 P=0.121
Mak RH. et al [20]	PhaseⅡ single institution (n=123)	NSCLC stage Ⅱb-Ⅲb No prior thoracic RT	Curative RT 41.4 Gy-74 Gy	With or without chemotherapy /surgery	LRR (%): 41.7 (39/94)  17.8 (5/29) P=0.005 2-year RFS%: 35.8    41.4 P=0.33			34.7   61.2 P=0.05
Lee HL. et al [21]	PhaseⅡ single institution (n=43)	NSCLC with brain metastases	WBRT 30 Gy-40 Gy/15 f-20 f, 17 cases local boost to 50 Gy-60 Gy	With or without TKI	RR (%): 46 (6/13)  80 (24/30) P=0.037 RFS (month): 21.0    12.0 P=0.009			15.0   11.0 P=0.049